Using pharmacogenetics to personalize treatment outcome to ranibizumab (Lucentis) for the eye disease age-related macular degeneration (AMD)

药物Lucentis彻底改变了年龄相关性黄斑变性的治疗，这是澳大利亚严重视力丧失的最常见原因之一。不幸的是，高达25%的患者继续失去视力，尽管这种治疗。我们将使用最新的基因芯片技术来识别导致这种不良反应的遗传变异。拥有这些信息将使我们能够为患者提供个性化治疗，从而改善他们的视力。

The drug Lucentis has revolutionized the treatment of age-related macular degeneration, one of the commonest causes of severe vision loss in Australia. Unfortunately, up to 25% of patients continue to lose vision despite this treatment. We will use the latest gene chip technology to identify the genetic variant responsible for this poor response. Having this information will allow us to personalise treatment for the patient leading to improvement in their vision.